The World’s First Ovarian Tissue Dual-Activation Technology Selected into the 2025 "Shandong Outstanding Achievements Report" Project
Release time:
2025-10-13
According to recent announcements by the Jinan Municipal Bureau of Science and Technology, 11 outstanding achievements from Jinan have been included in the 2025 "Shandong Outstanding Achievements Report" project. Among them is the globally first-of-its-kind ovarian tissue dual-activation technology developed by Shandong Silver Med Life Science Research Institute (Jinan).
Addressing Infertility Challenges and Nurturing Hope for Childbearing
Shandong Silver Med Life Science Research Institute (hereinafter referred to as "Silver Med Institute") collaborated with a team led by Professor Wang Huiying and Dr. Jin Bo from Beijing University of Chinese Medicine Shenzhen Hospital to develop this "ovarian dual-activation" technology, marking another milestone in cryobiomedical science. By employing a "cryopreservation + PFC" dual-activation approach for ovarian tissue, the technology has enabled patients to achieve natural conception. To date, the first healthy baby born through this method has been delivered safely.
It is reported that this is the world’s first case of successful natural conception and live birth achieved by activating ovaries using this method. The application of this technology not only brings hope to patients with premature ovarian failure (POF) and infertility but also provides a brand-new solution for fertility preservation in female cancer patients of childbearing age.
World’s First Ovarian Dual-Activation Technology
The team innovatively combined the in vitro activation of primordial follicles (IVA) with autologous venous-derived cytokine (PFC) technology, offering safer, more effective, and personalized treatment options for patients with premature ovarian insufficiency (POI) and poor ovarian response (POR).
PFC technology involves concentrating, activating, and isolating various cell growth factors, cytokines, and related proteins from autologous venous blood using specialized methods, followed by standardized preparation processes such as lyophilization. Clinical studies have confirmed that these endogenous growth factors and cytokines can aid tissue regeneration, including activating dormant primordial follicles in the ovaries, promoting angiogenesis, and increasing ovarian volume.
For POI/POR patients, traditional methods struggle to activate and grow ovarian follicles. The team’s innovative IVA technology involves extracting a small sample of ovarian cortical tissue via laparoscopic surgery, combining it with cryopreservation and revival techniques, subjecting it to ex vivo cryogenic activation in the lab, and performing in situ transplantation approximately one hour later. This process softens and expands the atrophied ovarian tissue. Post-operative evaluations show improvements in ovarian volume, follicle count, and ovarian artery blood flow, with hormone levels returning to normal.
Cryogenic Technology Safeguards Female Fertility
Experts note that the ovarian dual-activation technology not only provides a safe and reliable new option for POI/POR patients but also offers choices for fertility preservation in cancer patients.
Current fertility preservation methods primarily include oocyte cryopreservation, embryo cryopreservation, and ovarian tissue cryopreservation. For males, sperm cryopreservation is the main approach. Among these, ovarian tissue cryopreservation and transplantation are internationally recognized as the most promising methods for fertility protection, serving as the sole option for prepubertal girls and childbearing-age women undergoing non-deferrable anticancer treatment.
Additionally, experts highlight the technology’s potential application in menopausal regulation. By cryopreserving ovarian tissue at a young age and transplanting it later in life, it may delay menopause, reduce reliance on hormone therapy, and slow aging.
Looking ahead, the Silver Med Institute will collaborate with Beijing University of Chinese Medicine Shenzhen Hospital (Longgang) to deepen research on original technologies in "fertility preservation," aiming to establish a comprehensive fertility preservation system. By applying cryopreservation technology more broadly and effectively in clinical practice, they strive to contribute to building a fertility-friendly society.
Latest developments
According to recent announcements by the Jinan Municipal Bureau of Science and Technology, 11 outstanding achievements from Jinan have been included in the 2025 "Shandong Outstanding Achievements Report" project. Among them is the globally first-of-its-kind ovarian tissue dual-activation technology developed by Shandong Silver Med Life Science Research Institute (Jinan).
Recently, Frigid Zone Medicine, an authoritative international journal in the field of cryomedicine, published an important review titled "Advances in the Detection Methods for Assessing the Viability of Cryopreserved Samples". Written by the team of Yinfeng Cryomedical Research Center, the article systematically reviews and analyzes various detection techniques currently used to evaluate the viability of cryopreserved cells, tissues, and organs. It also proposes key directions from the perspectives of methodological integration and future instrument development, offering crucial theoretical support and practical guidance for the long - term cryopreservation of complex tissues and organs.
Recently, the "Novel Technology for Ultra-Low Temperature Cryopreservation, Activation, and Transplantation of Human Ovarian Tissue," developed through a collaborative effort between Shandong Yinfeng Life Science Research Institute and Beijing University of Chinese Medicine Shenzhen Hospital, has been awarded the 2025 Shandong Refrigeration and Air Conditioning Science and Technology Award. This groundbreaking technology pioneers a new pathway for female fertility preservation, marking a significant leap in China’s interdisciplinary advancements in reproductive medicine and cryobiology.
On May 19, a delegation from the Chinese Training Workshop for Government Officials of Developing Countries visited the exhibition hall of Yinfeng Biological Group's Cryomedicine Research Center. Government officials from multiple countries gained in-depth insights into Yinfeng’s innovative achievements in cryobiomedicine, cell storage, genetic technology, and other fields. They engaged in discussions with the delegation on technology transfer and international cooperation, contributing to the building of a global community with a shared future for humanity.
On the morning of May 17, 2025, an immersive exploration into life sciences and cryomedicine concluded successfully at Jinan Yinfeng Biological Science Park. Hosted by the Shandong Yinfeng Life Science Research Institute, this event offered members a firsthand look into the research base through activities such as ultra-low temperature cryotherapy experiences, brainwave signal acquisition system trials, and expert panel discussions. Participants witnessed the infinite possibilities that cryogenic technology and life sciences hold for humanity.
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155507
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
